Ardelyx, Inc. Stock News

Q3 2026 total product revenue of $125.5 million , reflecting 19% growth year-over-year IBSRELA Q3 2026 revenue growth of 23% year-over-year to $96.3 million Strong financial position with $285.3 million in cash, cash equivalents and investments as of September 30, 2026 Enrollment completed ahead of schedule in Phase 3 Clinical Trial in CIC Conference call scheduled for 4:30 PM Eastern Time WALT...

Trial fully enrolled ahead of schedule Topline data expected in the second half of 2027 WALTHAM, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced that it has fully enrol...

Real-world analysis showed serum phosphate reductions following XPHOZAH initiation across all phosphate binder groups evaluated

Recognition includes Life Sciences Manufacturer CEO of the Year, Podcast Initiative, and Marketing Team of the Year Recognition includes Life Sciences Manufacturer CEO of the Year, Podcast Initiative, and Marketing Team of the Year

WALTHAM, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced its participation in a fireside chat at the Jefferies Global Healthcare Conference 2026 on June 3 at 9:55 a.m. ET...

WALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced the presentation of a data analysis evaluating the long-term impact of XPHOZAH® (tenapanor) on serum electrolytes and selected nutrition biom...